Avoid common mistakes on your manuscript.
Erratum to: Dermatol Ther (Heidelb) (2017) 7:81–96 DOI 10.1007/s13555-016-0161-2
The authors would like to publish an erratum to correct the mistakes in Fig. 4 legend and in the text under the heading “Study Assessments and Endpoints” in the published article. The correct texts are given below.
-
1.
Under the Fig. 4 legend the text currently reads: “a Partial clearance defined as ≤75% reduction in the number of clinically visible AK lesions. 5-FU/SA 5-fluorouracil 0.5%/salicylic acid 10%, AK actinic keratosis”.
The figure “≤75%” should be “≥75%”.
-
2.
The first paragraph of “Study Assessments and Endpoints” has repeated text. The text “and proportional change from baseline in the total number of lesions at each treatment visit and 8 weeks after the end of treatment.” should be removed.
Open Access
This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found under doi:10.1007/s13555-016-0161-2.
Rights and permissions
Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0), which permits use, duplication, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
About this article
Cite this article
Stockfleth, E., von Kiedrowski, R., Dominicus, R. et al. Erratum to: Efficacy and Safety of 5-Fluorouracil 0.5%/Salicylic Acid 10% in the Field-Directed Treatment of Actinic Keratosis: A Phase III, Randomized, Double-Blind, Vehicle-Controlled Trial. Dermatol Ther (Heidelb) 7, 263 (2017). https://doi.org/10.1007/s13555-017-0179-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13555-017-0179-0